The Honest Dose #11

Every so often I come across a compound that makes the case for this whole project better than I ever could, and today I’m covering one of those compounds.

Melanotan II is one of the most searched peptides on the internet. It has a nickname, a devoted following, and a summer season that reliably sends interest through the roof. It also has almost none of the human research you'd expect for something this widely used, a development history that got abandoned before the finish line, and documented safety signals that most of the marketing around it quietly leaves out. On paper it looks like a cautionary tale.

And yet it isn't a dead end, because the same research program that walked away from Melanotan II produced a compound that went all the way to FDA approval. Same origin, same receptor family, completely different ending. One became a grey-market research chemical. The other became a prescription drug.

That split is the most honest illustration I can give you of what the Research Quality Score is actually measuring. It isn't measuring whether a compound is interesting, or popular, or biologically plausible. Melanotan II is all three. It's measuring whether anyone did the work to prove it out in humans, and what happened when they tried. Two compounds can start from the exact same idea, and the only thing that separates a research chemical from a medicine is whether the trials got run and finished.

Let's get into it.

Melanotan II, known everywhere as MT-II or just "Melanotan 2," is a synthetic analog of alpha-melanocyte stimulating hormone, a natural hormone your body already makes. It works by activating a family of receptors called melanocortin receptors. Two of those matter for why people use it: MC1R, which drives melanin production and therefore skin tanning, and MC4R, which sits in pathways tied to sexual arousal. That dual action is exactly why the compound built the reputation it has, it produces a tan with far less sun exposure, and it has a well-known secondary effect on libido.

Here's the origin worth understanding. Melanotan II came out of research at the University of Arizona in the 1980s, built on the idea that if you could stimulate melanin production directly, you could produce a protective tan without the UV exposure that drives skin cancer. It was a genuinely reasonable scientific goal. But the compound that reached the grey market is not an approved drug, and it never became one. Development as a tanning agent was abandoned, and what's sold today circulates as an unapproved research chemical with no regulatory oversight anywhere in the world.

This is where the story gets genuinely interesting, and where the honest picture diverges hard from the marketing.

The core mechanism is real. Melanotan II does what it says on the receptor level, it's a potent non-selective melanocortin agonist, and its tanning and libido effects are not in dispute as effects. What's thin is the controlled human evidence base you'd want before calling something safe and effective for routine use. The compound has been studied in small early-stage human work and a good deal of preclinical research, but it never advanced through the large, controlled trials that establish a real safety and efficacy profile. Its development as a consumer tanning product was abandoned before it ever got there.

Then there's the branch that didn't get abandoned. Researchers took the same melanocortin work and pursued the MC4R sexual-function pathway specifically, refining the molecule into a compound called Bremelanotide. That one ran the full clinical gauntlet and earned FDA approval in 2019 as Vyleesi, a prescription treatment for low sexual desire in premenopausal women. It's in the catalog at a 69 ironically. So the melanocortin idea absolutely produced a validated medicine. It just wasn't Melanotan II. It was Melanotan II's more disciplined descendant, the one whose developers actually finished the trials.

The safety piece belongs in plain view, because the marketing rarely puts it there. Melanotan II carries documented concerns, the most discussed being that it stimulates all melanocytes, including the ones in existing moles, which can darken them and complicates the kind of mole monitoring that matters for catching skin cancer early. There are also reported effects on blood pressure and other systems. I want to be careful here about my lane: the RQS does not score safety, and I'm not issuing a safety verdict. But leaving these out entirely would be exactly the kind of omission this newsletter exists to correct.

Melanotan II is a real compound with a real mechanism, an enormous following, and a research base that never caught up to its popularity. Its most important lesson isn't about tanning at all. It's that being biologically plausible and being widely used are not the same as being proven, and that the honest dividing line between a research chemical and an approved drug is simply whether someone ran the trials to the end. The melanocortin field did produce an FDA-approved medicine. Melanotan II just isn't it.

RQS: 38/100 - Weak Evidence

Read the full Melanotan II profile

The claim: Tape your lips together before bed and wake up transformed. It's one of the biggest wellness trends of the last two years, pushed hard by celebrities, athletes, and a wall of before-and-after content. The promises stack up fast: deeper sleep, less snoring, better breathing, fresher breath, more energy, even a sharper jawline. It's cheap, it's simple, and it feels like a secret the sleep industry doesn't want you to know.

The reality: Start with the part that's actually legitimate, because there is one. Nasal breathing is genuinely better for you than mouth breathing. Your nose filters, humidifies, and warms the air, and it produces nitric oxide that helps with oxygen uptake. Chronic mouth breathing at night is linked to dry mouth, worse sleep, and other issues. So the underlying instinct, breathe through your nose, is sound. That's the kernel of truth the trend is built on.

The problem is the leap from "nasal breathing is good" to "so tape your mouth shut," and that's where the evidence falls apart. A 2025 systematic review published in PLOS One pulled together every study they could find on mouth taping, ten studies covering just over 200 patients total, and the verdict was blunt: the research is low quality across the board. Only a couple of studies showed measurable benefit, and those were in people with mild obstructive sleep apnea, not the general public. For most people, there's simply no good evidence that taping your mouth improves sleep quality, and the anti-aging and jawline claims have no real support at all.

More important is the safety finding, because this is where a harmless-sounding hack turns risky. If your nose is even partially blocked, from congestion, allergies, a deviated septum, or undiagnosed sleep apnea, taping your mouth shut removes your backup airway. Researchers flagged a real risk of asphyxiation for exactly these people, and the catch is that many of them don't know they have a nasal obstruction. The trend also quietly hides a bigger danger: if you're taping your mouth to stop snoring, you may be masking the symptoms of untreated sleep apnea, a serious condition, instead of getting it diagnosed.

The honest version of the claim: Nasal breathing is worth pursuing, but mouth taping is the wrong tool for it and a genuinely risky one for anyone with a blocked nose or undiagnosed apnea. The evidence behind the viral promises is thin to nonexistent, and the practice can hide a condition that needs real treatment. If you snore heavily or wake up exhausted, the move isn't a strip of tape, it's a conversation with a doctor about what's actually going on.

This is a general-health topic and nothing here is medical advice. Persistent snoring or daytime exhaustion can signal a treatable medical condition, and that's a question for a clinician, not a newsletter.

A 38 puts Melanotan II in the Weak band, and it's a useful score to sit with, because it's higher than a compound like PDA at 19 but well below its own approved cousin at 69. Both of those gaps are telling.

Why it clears the floor: unlike the compounds scoring in the teens, Melanotan II isn't an evidence vacuum. It has a genuinely characterized mechanism, it has been through early human study, and there's a real body of preclinical work behind it. There's something to actually evaluate, and what exists is legitimate as far as it goes. That's enough to lift it out of the Insufficient band.

Why it stays weak: the score is capped by what never happened. The large, controlled, late-stage human trials that would establish a real safety and efficacy profile were never completed, because the compound's development was abandoned. You cannot score late-phase evidence that doesn't exist. The RQS rewards the strength and completeness of human outcome data, and Melanotan II's data trails off exactly where it would need to get stronger.

The most instructive comparison is right inside its own family. Bremelanotide, its descendant, scores a 69 in the Moderate band, and the entire difference between a 38 and a 69 comes down to one thing: somebody finished the trials. Same receptor biology, same origin, same era of research. One got taken through controlled human studies to approval, the other got dropped. That 31-point spread isn't a judgment on the underlying science. It's a measurement of follow-through, which is precisely what the RQS is built to capture.

The "approved cousin" pattern is worth watching across the catalog.
Melanotan II and bremelanotide aren't the only example of a popular research compound sitting next to an approved relative that actually finished its trials. This pattern, where the hyped grey-market version and the validated medicine share a lineage, keeps showing up, and it's one of the clearest teaching tools I have for what separates real evidence from plausible hype. Expect me to keep drawing these lines as they appear, because the comparison does more to explain the RQS than any amount of methodology writing.

Melanotan II is a summer story, and the seasonal spike brings new users who skip the fine print.
Search interest in tanning compounds climbs every year as summer hits, and that surge tends to pull in people who find the tanning benefit long before they find the safety context. The mole-darkening concern is the one I'd most want a new user to know about, not because I'm issuing a safety verdict, but because it interacts with skin cancer screening in a way that genuinely matters and almost never makes it into the marketing. If someone you know is looking into this compound because of the season, the mole point is the single most useful thing to pass along.

The companion this issue writes itself, because it's the other half of the lead's story.

PT-141, sold as Vyleesi, is Melanotan II's direct descendant and the compound that took the melanocortin idea across the finish line. Where Melanotan II is a non-selective agonist hitting the whole receptor family, bremelanotide was refined to work centrally through MC4R, the sexual-desire pathway, and its developers ran it through the full sequence of controlled human trials. In June 2019 it earned FDA approval for hypoactive sexual desire disorder in premenopausal women, making it the only compound in the catalog's sexual-health category with a green light from the agency. Unlike the erectile-focused drugs that act on blood vessels, PT-141 works through the nervous system, a genuinely distinct mechanism.

It scores a 69, in the Moderate band, and the contrast with Melanotan II's 38 is the whole point of pairing them. These two compounds are close chemical relatives from the same research lineage. The difference in their scores has almost nothing to do with the elegance of the underlying biology, which they largely share, and almost everything to do with which one had a development team that saw the trials through to approval. Read side by side, they're the clearest case study in the catalog for what the RQS actually rewards: not the idea, but the evidence.

RQS: 69/100 - Moderate Evidence

Read the full PT-141 profile

Hopefully that was helpful/interesting, see you next week.

-Emeka

Peptidclear.com

You're receiving this because you signed up at peptideclear.com. No sponsors. No affiliate links. Just the research, translated.